What is the primary strategic rationale behind Amgen's acquisition of Five Prime Therapeutics?

The primary strategic rationale is to enhance Amgen's oncology pipeline. Five Prime's lead drug candidate, bemarituzumab, is a first-in-class antibody targeting fibroblast growth factor receptor 2b (FGFR2b), which is implicated in various solid tumors. This acquisition is expected to significantly strengthen Amgen's position in the oncology market.

What is the offer price for Five Prime Therapeutics shares, and how will the transaction be completed?

Amgen is offering to purchase all outstanding shares of Five Prime common stock for $38.00 per share in cash. The acquisition will be completed through a cash tender offer by Amgen's subsidiary, Franklin Acquisition Sub, Inc. If successful, Five Prime will then be merged with Amgen.

Are there any conditions or risks associated with this acquisition?

Yes, the acquisition is subject to several conditions, including the tender of a majority of Five Prime's outstanding shares, regulatory approvals (such as Hart-Scott-Rodino), and the absence of any material adverse effects on Five Prime. There are also risks related to the timing of the tender offer, potential competing offers, and the successful integration of Five Prime and its pipeline into Amgen.

What is the potential financial impact or value of this deal?

The offer price of $38.00 per share implies a total equity value of approximately $1.9 billion for Five Prime. Investors should note that this filing is an announcement of the agreement, and the ultimate financial impact will depend on the successful completion of the transaction and the future performance of the acquired assets, particularly bemarituzumab.

AMGN 8-K: Material Agreements & Regulation FD

Summary

Amgen Inc. (AMGN) announced on March 4, 2021, that it has entered into a definitive agreement to acquire Five Prime Therapeutics, Inc. in a cash tender offer. Amgen, through its subsidiary Franklin Acquisition Sub, Inc., will offer to purchase all outstanding shares of Five Prime common stock for $38.00 per share, in cash. The acquisition is expected to enhance Amgen's oncology pipeline, particularly with Five Prime's lead drug candidate, bemarituzumab. The transaction is subject to customary closing conditions, including a majority of Five Prime shares being tendered and regulatory approvals. Following the successful tender offer, Five Prime will be merged with Amgen, becoming a wholly owned subsidiary. The agreement includes standard provisions such as "no-shop" clauses for Five Prime and termination fees under certain circumstances, indicating a commitment from both parties to the deal while allowing for potential superior offers.

Key Highlights

1Amgen to acquire Five Prime Therapeutics for $38.00 per share in cash via a tender offer.
2The acquisition aims to bolster Amgen's oncology portfolio, notably through Five Prime's bemarituzumab (FPA144).
3The transaction values Five Prime at approximately $1.9 billion.
4The tender offer is contingent upon receiving at least 50% of Five Prime's outstanding shares.
5The agreement includes customary closing conditions, regulatory approvals (including HSR), and representations/warranties.
6Five Prime is subject to customary 'no-shop' provisions, with exceptions for superior offers.
7A termination fee of $76 million is payable by Five Prime under specific circumstances, such as accepting a superior proposal.

AMGEN INC 8-K Report, Material Agreement (Mar 4, 2021)

Summary

Key Highlights

Frequently Asked Questions